199 related articles for article (PubMed ID: 15834925)
21. The putative glioma tumor suppressor gene on chromosome 19q maps between APOC2 and HRC.
Rubio MP; Correa KM; Ueki K; Mohrenweiser HW; Gusella JF; von Deimling A; Louis DN
Cancer Res; 1994 Sep; 54(17):4760-3. PubMed ID: 8062276
[TBL] [Abstract][Full Text] [Related]
22. Haplotypes of nine single nucleotide polymorphisms on chromosome 19q13.2-3 associated with susceptibility of lung cancer in a Chinese population.
Yin J; Vogel U; Ma Y; Qi R; Wang H
Mutat Res; 2008 May; 641(1-2):12-8. PubMed ID: 18358500
[TBL] [Abstract][Full Text] [Related]
23. Oligodendrogliomas: new insights from the genetics and perspectives.
Alentorn A; Sanson M; Idbaih A
Curr Opin Oncol; 2012 Nov; 24(6):687-93. PubMed ID: 22913971
[TBL] [Abstract][Full Text] [Related]
24. Gene expression profiling and subgroup identification of oligodendrogliomas.
Huang H; Okamoto Y; Yokoo H; Heppner FL; Vital A; Fevre-Montange M; Jouvet A; Yonekawa Y; Lazaridis EN; Kleihues P; Ohgaki H
Oncogene; 2004 Aug; 23(35):6012-22. PubMed ID: 15208679
[TBL] [Abstract][Full Text] [Related]
25. [Loss of heterozygosity on chromosomes 1 and 19 in cases of primary brain tumour].
Born PW; Broholm H; Laursen H
Ugeskr Laeger; 2006 Oct; 168(44):3813-6. PubMed ID: 17118240
[TBL] [Abstract][Full Text] [Related]
26. Preferential loss of paternal 19q, but not 1p, alleles in oligodendrogliomas.
Sanson M; Leuraud P; Marie Y; Delattre JY; Hoang-Xuan K
Ann Neurol; 2002 Jul; 52(1):105-7. PubMed ID: 12112056
[TBL] [Abstract][Full Text] [Related]
27. Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features.
Jenkinson MD; du Plessis DG; Smith TS; Joyce KA; Warnke PC; Walker C
Brain; 2006 Jul; 129(Pt 7):1884-91. PubMed ID: 16670176
[TBL] [Abstract][Full Text] [Related]
28. Chromosome 19q deletions in human gliomas overlap telomeric to D19S219 and may target a 425 kb region centromeric to D19S112.
Yong WH; Chou D; Ueki K; Harsh GR; von Deimling A; Gusella JF; Mohrenweiser HW; Louis DN
J Neuropathol Exp Neurol; 1995 Sep; 54(5):622-6. PubMed ID: 7666049
[TBL] [Abstract][Full Text] [Related]
29. Novel genomic alterations and mechanisms associated with tumor progression in oligodendroglioma and mixed oligoastrocytoma.
Blesa D; Mollejo M; Ruano Y; de Lope AR; Fiaño C; Ribalta T; García JF; Campos-Martín Y; Hernández-Moneo JL; Cigudosa JC; Meléndez B
J Neuropathol Exp Neurol; 2009 Mar; 68(3):274-85. PubMed ID: 19225409
[TBL] [Abstract][Full Text] [Related]
30. [Diagnostic and prognostic values of 1p and 19q deletions in adult gliomas: critical review of the literature and implications in daily clinical practice].
Fontaine D; Vandenbos F; Lebrun C; Paquis V; Frenay M
Rev Neurol (Paris); 2008; 164(6-7):595-604. PubMed ID: 18565359
[TBL] [Abstract][Full Text] [Related]
31. Oligodendrogliomas: clinical significance of 1p and 19q chromosomal deletions.
Sonabend AM; Lesniak MS
Expert Rev Neurother; 2005 Nov; 5(6 Suppl):S25-32. PubMed ID: 16274268
[TBL] [Abstract][Full Text] [Related]
32. Caveolin 1 expression independently predicts shorter survival in oligodendrogliomas.
Senetta R; Trevisan E; Rudà R; Maldi E; Molinaro L; Lefranc F; Chiusa L; Lanotte M; Soffietti R; Cassoni P
J Neuropathol Exp Neurol; 2009 Apr; 68(4):425-31. PubMed ID: 19287309
[TBL] [Abstract][Full Text] [Related]
33. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss.
Griffin CA; Burger P; Morsberger L; Yonescu R; Swierczynski S; Weingart JD; Murphy KM
J Neuropathol Exp Neurol; 2006 Oct; 65(10):988-94. PubMed ID: 17021403
[TBL] [Abstract][Full Text] [Related]
34. Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma.
Cairncross G; Jenkins R
Cancer J; 2008; 14(6):352-7. PubMed ID: 19060598
[TBL] [Abstract][Full Text] [Related]
35. [Histological and molecular classification of gliomas].
Figarella-Branger D; Colin C; Coulibaly B; Quilichini B; Maues De Paula A; Fernandez C; Bouvier C
Rev Neurol (Paris); 2008; 164(6-7):505-15. PubMed ID: 18565348
[TBL] [Abstract][Full Text] [Related]
36. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma.
Sahm F; Reuss D; Koelsche C; Capper D; Schittenhelm J; Heim S; Jones DT; Pfister SM; Herold-Mende C; Wick W; Mueller W; Hartmann C; Paulus W; von Deimling A
Acta Neuropathol; 2014 Oct; 128(4):551-9. PubMed ID: 25143301
[TBL] [Abstract][Full Text] [Related]
37. Identification of novel oligodendroglioma-associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling.
Tews B; Felsberg J; Hartmann C; Kunitz A; Hahn M; Toedt G; Neben K; Hummerich L; von Deimling A; Reifenberger G; Lichter P
Int J Cancer; 2006 Aug; 119(4):792-800. PubMed ID: 16550607
[TBL] [Abstract][Full Text] [Related]
38. Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors.
Walker C; Haylock B; Husband D; Joyce KA; Fildes D; Jenkinson MD; Smith T; Broome J; du Plessis DG; Warnke PC
Neurology; 2006 Jun; 66(11):1661-7. PubMed ID: 16769937
[TBL] [Abstract][Full Text] [Related]
39. ETV/Pea3 family transcription factor-encoding genes are overexpressed in CIC-mutant oligodendrogliomas.
Padul V; Epari S; Moiyadi A; Shetty P; Shirsat NV
Genes Chromosomes Cancer; 2015 Dec; 54(12):725-33. PubMed ID: 26357005
[TBL] [Abstract][Full Text] [Related]
40. No preferential loss of paternal 19q alleles in oligodendroglial tumors.
Hartmann C; Mueller W; Lass U; Stockhammer F; von Eckardstein K; Veelken J; Jeuken J; Wick W; von Deimling A
Ann Neurol; 2003 Aug; 54(2):256-8. PubMed ID: 12891681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]